| 摘要 |
PURPOSE:A carcinostatic agent containing saikosaponin a or saikosaponin d as a main component. CONSTITUTION:A carcinostatic agent containing a compound shown by the formula I or formula II as a main component. A dose is 200-300mg/person daily, 1-3 times daily preferably by oral administration. A solution, powder, granule, tablet, suppository, enteric agent, capsule, etc. may be used as the dosage form. The compound shown by the formula I or formula II is obtained by extracting root of Bupleurum falcatum L. with an aqueous medium such as an alcohol (e.g, methanol, ethanol, etc.), distilling away the solvent from the extracted solution, blending the essence with an ether, heating it, removing the ether layer to give the residue, partitioning the residue with a water- insoluble organic solvent (e.g., n-butanol, ethyl acetate, etc.) and water, subjecting the water-insoluble organic solvent layer to high-speed liquid chromatography, to give the compound shown by the formula I after 14 minutes and the compound shown by the formula II after 36 minutes. |
